- cafead May 15, 2024 at 11:52: AM
via The US Food and Drug Administration (FDA) has cleared Verismo Therapeutics’ investigational new drug (IND) application to advance its CAR-T therapy SynKIR-310 into a Phase I clinical trial.
The Phase I CELESTIAL-301 trial will enrol patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), whether they have had prior CAR-T therapy or not.
article source
The Phase I CELESTIAL-301 trial will enrol patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), whether they have had prior CAR-T therapy or not.
article source